Jeil Pharmaceutical's Phase 2 Diabetes Therapy Results Published in DMJ
Published in an SCI-Indexed International Journal
"Efficacy and Safety in Glycemic Improvement Confirmed"
Jeil Pharmaceutical has confirmed meaningful improvements in postprandial blood glucose and glycated hemoglobin (HbA1c) with the publication of phase 2 clinical trial results for its independently developed oral type 2 diabetes treatment in an international academic journal.
On July 30, Jeil Pharmaceutical announced that a paper covering the phase 2 clinical results of its oral type 2 diabetes drug candidate, JP-2266—a SGLT-1/2 (Sodium-Glucose Co-Transporter 1/2) inhibitor—has been published in the Diabetes and Metabolism Journal (DMJ).
DMJ is an SCI(E)-indexed international journal publishing the latest research in diabetes and metabolic diseases. With a recently announced impact factor (IF) of 8.2, DMJ is widely recognized internationally in the field of endocrinology and metabolism for its scholarly impact and standing as a research journal.
Clinical phase 2 results of JP-2266, a type 2 diabetes treatment from Jeil Pharmaceutical. A significant difference was observed in the change of glycated hemoglobin compared to the placebo. Jeil Pharmaceutical
View original imageJP-2266 is a dual-action inhibitor that combines an SGLT-2 inhibitory mechanism, which suppresses glucose reabsorption in the kidneys, with an SGLT-1 inhibitor that delays glucose absorption in the intestines.
This study was a randomized, double-blind, placebo-controlled, multicenter phase 2 clinical trial designed to evaluate the efficacy and safety of JP-2266 and to explore the optimal dosage in type 2 diabetes patients with glycated hemoglobin (HbA1c) levels between 7.0% and 10.0% whose glucose is not adequately controlled by diet and exercise alone. The trial coordinator was Professor Bong Soo Cha of the Department of Endocrinology at Yonsei University College of Medicine, Severance Hospital. The study ran from December 2023 to December 2024 at 28 medical institutions in Korea, enrolling a total of 156 patients.
According to the published clinical paper, JP-2266 significantly reduced HbA1c levels at week 12 compared to placebo. The estimated treatment difference (ETD) versus placebo was -0.94% for the JP-2266 5 mg group and -0.97% for the 10 mg group, both showing statistically significant improvement (P<0.0001 for both).
The proportion of patients achieving an HbA1c level below 7.0%, a primary treatment goal in diabetes management, was 70.6% in the JP-2266 10 mg group and 66.7% in the 5 mg group. This result demonstrates that a considerable number of patients reached the recommended target blood glucose level, further supporting the clinical efficacy and therapeutic potential of JP-2266.
In addition to HbA1c, fasting blood glucose also decreased at week 12 in both the JP-2266 5 mg and 10 mg groups, with significant improvements (P<0.0001 for both). Moreover, both postprandial one-hour and two-hour blood glucose levels dropped significantly; the reduction in postprandial two-hour glucose at week 12 was approximately 63 to 68 mg/dL in both the 5 mg and 10 mg groups (P<0.0001 for both).
Notably, JP-2266 was shown in this study to provide not only glycemic control but also weight reduction and improvements in certain cardiovascular and metabolic risk factors. Weight loss was observed in the study population with a mean body mass index (BMI) of 26.0, and systolic blood pressure decreased in the 10 mg treatment group. Improvements were also seen in indicators reflecting insulin resistance and beta-cell function.
In terms of safety, both doses of JP-2266 were generally well tolerated, with adverse event rates comparable to the placebo group. Most adverse events were mild or moderate in intensity, and all cases resolved during the follow-up period.
This study confirmed that JP-2266 simultaneously improved glycemic control, body weight, and blood pressure, demonstrating its potential as a treatment option for comprehensive management of type 2 diabetes. In particular, the strong postprandial glucose reduction based on the SGLT-1 inhibitory mechanism, which delays intestinal glucose absorption, suggests that JP-2266 may be developed as a differentiated therapeutic for Asian markets, where carbohydrate intake is relatively high.
Professor Bong Soo Cha of the Department of Endocrinology at Yonsei University College of Medicine, Severance Hospital said, “The effect of lowering postprandial glucose by slowing intestinal glucose absorption through SGLT-1 inhibition is a mechanistic feature that distinguishes JP-2266 from conventional SGLT-2 inhibitors.” He continued, “By alleviating postprandial glucose peaks, it is expected to reduce the acute workload on the pancreas for insulin secretion and help mitigate beta-cell overload.”
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
He added, “Given the heightened importance of postprandial glucose management in Asian countries with high carbohydrate consumption, the mechanistic characteristics of JP-2266 may offer clinically meaningful treatment options. However, since these results are based on a phase 2 clinical trial, further phase 3 studies are necessary for additional verification of its efficacy and safety.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.